Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Core Insights - Shattuck Labs, Inc. is participating in a panel discussion at the United European Gastroenterology Week (UEGW) Conference 2025, focusing on key takeaways from the event [1] - The panel will be moderated by analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Marla Dubinsky, M.D. [1] Conference Details - The panel discussion titled "Wedbush UEGW Conference 2025 Rewind" will take place on October 8, 2025, from 10:00 am to 12:00 pm EST [2] - Shattuck's CEO, Taylor Schreiber, M.D., Ph.D., will represent the company during the session [2] Product Information - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at achieving a complete and durable blockade of the DR3/TL1A pathway [2] - Preclinical studies of SL-325 show high affinity binding and superior activity compared to TL1A antibodies, indicating potential for higher efficacy and lower immunogenicity [2] - SL-325 is currently undergoing a Phase 1 clinical trial [2] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on inflammatory bowel disease (IBD) [3] - The company leverages its expertise in protein engineering to develop novel TNF receptor therapeutics, with SL-325 being its lead program [3] - Shattuck Labs operates offices in Austin, Texas, and Durham, North Carolina [3]